Literature DB >> 10607891

[Nphe(1)]nociceptin-(1-13)-NH(2) antagonizes nociceptin effects in the mouse colon.

A Rizzi1, R Bigoni, G Caló, R Guerrini, S Salvadori, D Regoli.   

Abstract

Nociceptin, nociceptin-(1-13)-NH(2), Ac-RYYRWK-NH(2), [Phe(1)psi(CH(2)&z.sbnd;NH)Gly(2)]nociceptin-(1-13)-NH(2), the new nociceptin analog [Nphe(1)]nociceptin-(1-13)-NH(2), and endomorphin-1 have been tested in the isolated mouse colon. All peptides, except [Nphe(1)]nociceptin-(1-13)-NH(2), caused concentration-dependent, tetrodotoxin-sensitive contractions showing similar maximal effects. Naloxone (1 microM) blocked the effect of endomorphin-1 but not that of the other peptides. [Nphe(1)]nociceptin-(1-13)-NH(2) (10 microM) was inactive against endomorphin-1, but antagonized the contractile effects of nociceptin receptor ligands showing similar pA(2) values (approximately 6.0). The present findings indicate that [Nphe(1)]nociceptin-(1-13)-NH(2) is a low-potency, selective nociceptin receptor antagonist, devoid of residual agonist activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10607891     DOI: 10.1016/s0014-2999(99)00730-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  [Nphe(1)]-Nociceptin (1-13)-NH(2), a nociceptin receptor antagonist, reverses nociceptin-induced spatial memory impairments in the Morris water maze task in rats.

Authors:  J P Redrobe; G Calo; R Guerrini; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 2.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin.

Authors:  S Sbrenna; M Marti; M Morari; G Calo'; R Guerrini; L Beani; C Bianchi
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

4.  Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist.

Authors:  G Calo'; R Guerrini; R Bigoni; A Rizzi; G Marzola; H Okawa; C Bianchi; D G Lambert; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

5.  [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.

Authors:  Girolamo Calo; Anna Rizzi; Daniela Rizzi; Raffaella Bigoni; Remo Guerrini; Giuliano Marzola; Matteo Marti; John McDonald; Michele Morari; David G Lambert; Severo Salvadori; Domenico Regoli
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

6.  In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.

Authors:  Federica Ferrari; Maria Camilla Cerlesi; Davide Malfacini; Laila Asth; Elaine C Gavioli; Blair V Journigan; Uma Gayathri Kamakolanu; Michael E Meyer; Dennis Yasuda; Willma E Polgar; Anna Rizzi; Remo Guerrini; Chiara Ruzza; Nurulain T Zaveri; Girolamo Calo
Journal:  Eur J Pharmacol       Date:  2016-10-22       Impact factor: 4.432

Review 7.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

8.  Nociceptin effect on intestinal motility depends on opioid-receptor like-1 receptors and nitric oxide synthase co-localization.

Authors:  Andrei Sibaev; Jakub Fichna; Dieter Saur; Birol Yuece; Jean-Pierre Timmermans; Martin Storr
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

9.  NOP receptor pharmacological profile - A dynamic mass redistribution study.

Authors:  Davide Malfacini; Katharina Simon; Claudio Trapella; Remo Guerrini; Nurulain T Zaveri; Evi Kostenis; Girolamo Calo'
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.